Kasim Kutay

Supporting Chelsea and Westminster Hospital NHS Foundation Trust. We enable every patient to receive outstanding care, in our Trust’s community of more than a million people and beyond. Our generous supporters and partners enable us to: - Build new facilities, invest in health innovations and bring the latest technologies to our hospitals. - Deliver a unique arts in health programme to transform the hospital experience and clinical environment. - Support research to help improve treatments and care for patients.

At Convatec, #ForeverCaring is our promise to patients & healthcare providers, as we deliver pioneering trusted medical solutions to improve the lives we touch. #ForeverConvatec

Gimv is a European investment company with more than 40 years​ experience in private equity. Listed on Euronext Brussels, Gimv currently has EUR 1.5 billion of assets under management. The portfolio contains around 60 portfolio companies, with a combined turnover of EUR 3.7 billion and more than 20,000 employees. As a recognized market leader in selected investment platforms, Gimv identifies entrepreneurial and innovative companies with high-growth potential and supports them in their transformation into market leaders. Gimv’s five investment platforms are: Consumer, Healthcare, Life Sciences, Smart Industries and Sustainable Cities. Each of these platforms works with a skilled and dedicated team across Gimv’s home markets of the Benelux, France and Germany and can count on an extended international network of experts. We are a strategic partner for ambitious companies wanting to grow into leaders in their sectors. We help them plan ways to speed up their expansion. We take a flexible approach based on our solid balance sheet, patient capital and long-term view. Hand-in-hand with growth companies, we are working on innovative solutions for tomorrow’s society. More information on Gimv can be found on www.gimv.com.

Supporting Chelsea and Westminster Hospital NHS Foundation Trust. We enable every patient to receive outstanding care, in our Trust’s community of more than a million people and beyond. Our generous supporters and partners enable us to: - Build new facilities, invest in health innovations and bring the latest technologies to our hospitals. - Deliver a unique arts in health programme to transform the hospital experience and clinical environment. - Support research to help improve treatments and care for patients.

At Convatec, #ForeverCaring is our promise to patients & healthcare providers, as we deliver pioneering trusted medical solutions to improve the lives we touch. #ForeverConvatec

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. Our unordinary mindset is at the heart of everything we do. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 68,800 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html